DE10199049I2 - Pharmakologisch wirksame 3-substituierte 1, 5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung - Google Patents

Pharmakologisch wirksame 3-substituierte 1, 5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung

Info

Publication number
DE10199049I2
DE10199049I2 DE2001199049 DE10199049C DE10199049I2 DE 10199049 I2 DE10199049 I2 DE 10199049I2 DE 2001199049 DE2001199049 DE 2001199049 DE 10199049 C DE10199049 C DE 10199049C DE 10199049 I2 DE10199049 I2 DE 10199049I2
Authority
DE
Germany
Prior art keywords
pyrazoles
diaryl
substituted
preparation
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199049
Other languages
English (en)
Other versions
DE10199049I1 (de
Inventor
Rene Nordmann
Trevor James Petcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of DE10199049I1 publication Critical patent/DE10199049I1/de
Publication of DE10199049I2 publication Critical patent/DE10199049I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DE2001199049 1986-05-29 1987-05-28 Pharmakologisch wirksame 3-substituierte 1, 5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung Active DE10199049I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86799686A 1986-05-29 1986-05-29
US07/042,661 US4826868A (en) 1986-05-29 1987-04-29 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use

Publications (2)

Publication Number Publication Date
DE10199049I1 DE10199049I1 (de) 2002-01-10
DE10199049I2 true DE10199049I2 (de) 2003-01-09

Family

ID=26719497

Family Applications (2)

Application Number Title Priority Date Filing Date
DE87304720T Expired - Lifetime DE3788244T2 (de) 1986-05-29 1987-05-28 Pharmakologisch wirksame 3-substituierte 1,5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung.
DE2001199049 Active DE10199049I2 (de) 1986-05-29 1987-05-28 Pharmakologisch wirksame 3-substituierte 1, 5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE87304720T Expired - Lifetime DE3788244T2 (de) 1986-05-29 1987-05-28 Pharmakologisch wirksame 3-substituierte 1,5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung.

Country Status (21)

Country Link
US (1) US4826868A (de)
EP (1) EP0248594B1 (de)
JP (1) JP2512751B2 (de)
KR (1) KR960007163B1 (de)
CN (1) CN1028227C (de)
AU (1) AU596844B2 (de)
CA (1) CA1337122C (de)
DE (2) DE3788244T2 (de)
DK (1) DK170202B1 (de)
ES (1) ES2059377T3 (de)
FI (1) FI94340C (de)
HK (1) HK14094A (de)
HU (1) HU221300B1 (de)
IE (1) IE63856B1 (de)
IL (1) IL82671A0 (de)
LU (1) LU90829I2 (de)
NL (1) NL300057I2 (de)
NO (2) NO172236C (de)
NZ (1) NZ220353A (de)
PH (1) PH25126A (de)
PT (1) PT84964B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898952A (en) * 1987-05-29 1990-02-06 Ortho Pharmaceutical Corporation Regioselective synthesis of a 1,5-disubstituted pyrazole
JPS63307841A (ja) * 1987-05-29 1988-12-15 オーソ・フアーマシユーチカル・コーポレーシヨン １，５‐ジ置換ピラゾール類の製造法
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
EP0442448A3 (en) 1990-02-13 1992-08-12 Bristol-Myers Squibb Company Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2052950A1 (en) * 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5260458A (en) * 1991-09-26 1993-11-09 Ortho Pharmaceutical Corporation 2-oxo tetrahydrofuran compounds
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5387602A (en) * 1993-08-30 1995-02-07 Ortho Pharmaceutical Corporation 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
AU4527996A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
CZ299710B6 (cs) * 1999-08-03 2008-10-29 Ortho-Mcneil Pharmaceutical, Inc. Zpusob prípravy 1,5-diaryl-3-substituovaného pyrazolu
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265394A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004037793A1 (ja) * 2002-10-24 2004-05-06 Wakamoto Pharmaceutical Co., Ltd. シクロオキシゲナーゼ及び５−リポキシゲナーゼを阻害するピラゾール−４−アルカン酸誘導体
US7183306B2 (en) * 2002-12-02 2007-02-27 Astellas Pharma Inc. Pyrazole derivatives
CA2520870A1 (en) * 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1641762A2 (de) * 2003-07-02 2006-04-05 Janssen Pharmaceutica N.V. Cck-1 rezeptor modulatoren
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
EP1663999A2 (de) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitoren der phosphodiesterase iv
EP1675585A2 (de) * 2003-10-17 2006-07-05 Tanabe Seiyaku Co., Ltd. Kalzium-aktivierter k kanalöffner mit grosser leitfähigkeit
EP1694655A2 (de) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
EP1781617A4 (de) * 2004-06-30 2009-06-24 Janssen Pharmaceutica Nv Alpha, beta-ungesättigte ester und säuren durch stereoselektive dehydratisierung
EP1934219A1 (de) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituierte pyrazolo-[3,4-b]-pyridine als phosphodiesterase-inhibitoren
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP1958947A1 (de) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitoren für Phosphodiesterase Typ 4
EP2124944B1 (de) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridin-Derivate als Phosphodiesterasehemmer
EP2124943A1 (de) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridinderivate als phosphodiesterasehemmer
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2353598A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
EP2395003A1 (de) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazolverbindungen als Sigmarezeptor-Inhibitoren
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161645A1 (en) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CA2803880C (en) * 2010-06-28 2018-09-25 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
US8492424B2 (en) * 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP3406598B1 (de) 2012-06-14 2020-01-29 Mayo Foundation for Medical Education and Research Pyrazolderivate als hemmer von stat3
BR112016013754A2 (pt) 2013-12-17 2017-08-08 Esteve Labor Dr Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755924A (fr) * 1969-09-12 1971-02-15 Byk Gulden Lomberg Chem Fab Derives d'acide pyrazole-4-acetique, leur procede de preparation et medicaments en contenant
GB1373212A (en) * 1970-12-07 1974-11-06 Wyeth John & Brother Ltd Pyrazole compounds
US3974176A (en) * 1973-08-16 1976-08-10 Byk-Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them
DE2633992A1 (de) * 1975-08-08 1978-02-09 Schering Ag Neue pyrazol-derivate, ihre herstellung und verwendung
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
DE3205187A1 (de) * 1982-02-13 1983-08-25 Hoechst Ag, 6230 Frankfurt Substituierte phenylpyrazolderivate, verfahren zu ihrer herstellung, arzneimittel auf basis dieser verbindungen, sowie deren verwendung

Also Published As

Publication number Publication date
NO872228L (no) 1987-11-30
DE3788244T2 (de) 1994-04-14
IE63856B1 (en) 1995-06-14
HUT68247A (en) 1995-06-28
KR960007163B1 (ko) 1996-05-29
HK14094A (en) 1994-03-04
EP0248594A3 (en) 1988-11-17
NL300057I1 (nl) 2001-12-01
JP2512751B2 (ja) 1996-07-03
FI94340B (fi) 1995-05-15
CA1337122C (en) 1995-09-26
NO172236B (no) 1993-03-15
FI872379A (fi) 1987-11-30
NL300057I2 (nl) 2002-01-02
FI94340C (fi) 1995-08-25
EP0248594A2 (de) 1987-12-09
PT84964B (pt) 1990-02-08
FI872379A0 (fi) 1987-05-28
US4826868A (en) 1989-05-02
NO872228D0 (no) 1987-05-27
DE3788244D1 (de) 1994-01-05
DK273587D0 (da) 1987-05-27
IL82671A0 (en) 1987-11-30
PT84964A (en) 1987-06-01
CN1028227C (zh) 1995-04-19
KR870011100A (ko) 1987-12-21
CN87103953A (zh) 1987-12-09
HU221300B1 (en) 2002-09-28
EP0248594B1 (de) 1993-11-24
DK273587A (da) 1987-11-30
AU7360887A (en) 1987-12-10
DK170202B1 (da) 1995-06-12
DE10199049I1 (de) 2002-01-10
NZ220353A (en) 1989-05-29
ES2059377T3 (es) 1994-11-16
JPS6322080A (ja) 1988-01-29
PH25126A (en) 1991-02-19
NO2001016I1 (no) 2001-10-01
LU90829I2 (fr) 2001-11-12
IE871403L (en) 1987-11-29
AU596844B2 (en) 1990-05-17
NO172236C (no) 1993-06-23

Similar Documents

Publication Publication Date Title
DE10199049I2 (de) Pharmakologisch wirksame 3-substituierte 1, 5-Diaryl-pyrazole und Verfahren zu ihrer Herstellung
DE68907876T2 (de) Substanz DC 113 und Verfahren zu ihrer Herstellung.
DE68921548D1 (de) Poröse Strukture und Verfahren zu ihrer Herstellung.
DE3786781T2 (de) 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-en-2-carbonsäure-Derivate und Verfahren zu deren Herstellung.
DE3782994T2 (de) Erythromycin-a-derivate und verfahren zu ihrer herstellung.
PT84460A (de) 1,1-disubstituierte cyclopropanderivate verfahren zu ihrer herstellung und ihre verwendung
ATE83605T1 (de) Pestizide zusammensetzungen und verfahren zu ihrer herstellung.
DE3588039T2 (de) Azetidinonderivate und Verfahren zu ihrer Herstellung.
DE3789466T2 (de) 3,7-Disubstituierte-3-Cephemverbindungen und Verfahren zu ihrer Herstellung.
DE3789569D1 (de) Zementzusammensetzung und Verfahren zu ihrer Herstellung.
DE3850363D1 (de) Carboxymethylsulfoethylcellulose und Verfahren zu ihrer Herstellung.
DE69114420D1 (de) Organozyklosiloxane und Verfahren zu ihrer Herstellung.
DE3786452T2 (de) Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
DE3888529D1 (de) Tylosinderivate und Verfahren zu ihrer Herstellung.
DE69012655T2 (de) Alpha-(omega-cyanoalkanoyl)-gamma-butyrolactone und Verfahren zu ihrer Herstellung.
DE3778517D1 (de) 7-brom-beta-carbolin-derivate und verfahren zu ihrer herstellung.
DE3884551T2 (de) Radioaktive Benzodiazepinderivate und Verfahren zu ihrer Herstellung.
DE69017091T2 (de) Cyclomalto-oligosaccharidderivate und Verfahren zu ihrer Herstellung.
DE3788489D1 (de) Fe7C3-enthaltende Partikel und Verfahren zu ihrer Herstellung.
DE3880490T2 (de) Perfluoramino-oxaziridine und Verfahren zu ihrer Herstellung.
DE3887293D1 (de) Si, Si'-Diorganyl-N-alkyl-tetrachlor-disilazane und Verfahren zu ihrer Herstellung.
DE68914500T2 (de) Alkylarylsulfone und Verfahren zu ihrer Herstellung.
ATE97660T1 (de) Pharmakologisch wirksame 3-substituierte 1,5diaryl-pyrazole und verfahren zu ihrer herstellung.
DE3688287T4 (de) Spirodiphosphoamidatverbindungen und Verfahren zu ihrer Herstellung.
DE59005327D1 (de) Substituierte Tetrachalkogenfulvalene und Verfahren zu deren Herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition